web analytics
Pubblicità

di Giancarlo Nicoli

From the press release.

ST. LOUIS, Oct. 28 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq:STXSNews) announced today the appointment of Pierre Rivaux as Vice President, Europe, Middle East, Africa (EMEA) to lead the Company’s EMEA operations and sales efforts in continuing to drive increased capital sales and utilization of its Niobe® Remote Magnetic Navigation System and Odyssey™ system. Mr. Rivaux will report directly to Michael P. Kaminski, President and CEO of Stereotaxis.

“Pierre brings over 20 years of international sales and broad executive experience in the medical device industry that enhances Stereotaxis’ focus on driving future sales growth in Europe and other key international markets,” said Mr. Kaminski. “Pierre’s extensive experience in Europe, strong leadership and expertise in selling high-tech medical/surgical disposables and capital equipment, as well as in building effective international teams and global sales operations will be tremendous assets as we continue to execute on our strategy to drive commercial success of our innovative technology platforms, Niobe and Odyssey.”

Mr. Rivaux previously held various management positions at Intuitive Surgical, including Vice President of International Sales & Marketing, President and CEO of Intuitive Surgical SA France and CEO of Intuitive Surgical Sarl in Switzerland, where he was responsible for implementing a new sales, marketing and finance organization focused on Europe (direct and distribution), Middle East, Africa, India, Asia and Latin America. Prior to that, from 2000 to 2004, Mr. Rivaux held management positions across Europe with Tyco Healthcare, most recently serving as Vice President of Central Europe. He was also the President and CEO of Tyco Healthcare France. Before that, he worked at Kendall S.A., most recently as President, CEO and General Manager of Kendall Incontinence. He earned his graduate degree at the Lille Graduate School of Management in 1985.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis’ Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, the effect of global  economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Source: Stereotaxis, Inc.

Comments

Leave a Reply

You must be logged in to post a comment.

%d bloggers like this: